Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements study observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which